Klin Onkol 2004; 17(2): 64-67.
Summary: Malignant cells in multiple myeloma produce a monoclonal immunoglobulin which is tumor-specific and can be used for the induction of T lymphocytes.The idiotype (Id) is expressed at the cell surface of malignant plasma cells and allow the recognition and targeting of these cells by Id-specific T lymphocytes. Vaccination using Id-protein has been attempted in patients with multiple myeloma and other B cell maligancies. The induced humoral and cellular immune response controls the growth of the malignant cell clone. The aim of this therapy is to induce specific immune response directed against the tumor cells. A phase II clinical study has started in our center, investigating the efficacy and toxicity of Id conjugated with keyhole limpet hemocyanin (KLH) given as a vaccine with or without interleukin-2 to patients with multiple myeloma. The vaccine is to be used in 12 patients with stable disease or with slow progression not requiring systemic therapy. No significant toxicities were seen during the first series of vaccination. It is not yet possible to evaluate clinical and immunological responses to the vaccine.
